• Whitehawk Therapeutics entered an option agreement with Hangzhou DAC to use the CPT113 linker-payload in up to five additional internally developed antibody-drug conjugate programs, expanding its clinical pipeline plan over the next 12-24 months.
• Clinical results supporting CPT113 have already been accepted for presentation, with Hangzhou DAC’s DXC006 Phase 1 data scheduled for an oral session at ASCO and described as showing clinical activity with a favorable safety profile.
• Whitehawk’s own Phase 1 dose-escalation studies of HWK-007 and HWK-016 are currently enrolling, with early data expected in the first half of 2027.
• A trials-in-progress poster on the HWK-007 Phase 1 study design will be presented at ASCO on May 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605211705PR_NEWS_USPR_____LA65551) on May 21, 2026, and is solely responsible for the information contained therein.